The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial - Nature Medicine In this phase 2, randomized trial in early Alzheimer’s disease, the TREM2 agonistic antibody AL002 showed target engagement but did not meet the primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes score.

In this phase 2, randomized trial in early #Alzheimers disease, the #TREM2 agonistic antibody AL002 showed target engagement but did not meet the primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes. #microglia #AD
https://www.nature.com/articles/s41591-026-04273-1

The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial - Nature Medicine In this phase 2, randomized trial in early Alzheimer’s disease, the TREM2 agonistic antibody AL002 showed target engagement but did not meet the primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes score.

In this phase 2, randomized trial in early #Alzheimers disease, the #TREM2 agonistic antibody AL002 showed target engagement but did not meet the primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes. #microglia #AD
https://www.nature.com/articles/s41591-026-04273-1

The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial - Nature Medicine In this phase 2, randomized trial in early Alzheimer’s disease, the TREM2 agonistic antibody AL002 showed target engagement but did not meet the primary endpoint of change from baseline in Clinical De...

Results from the #INVOKE2 phase 2 trial of the #TREM2 agonistic #antibody #AL002 in early #Alzheimers disease out now. Although #AL002 showed target engagement, no change in CDR-SB was seen. #microglia #dementia #AD
www.nature.com/articles/s41...

¿Tumores que frenan el Alzheimer? La pista: cistatina C Cáncer y Alzheimer, conectados por una proteína: cistatina C cruza al cerebro, activa TREM2 y reduce amiloide en ratones en vivo, según Cell. En un trabajo publicado en Cell y firmado por un equipo de...

¿Tumores que frenan el Alzheimer? La pista: cistatina C #Alzheimer #Cancer #Neurociencia #Investigacion #Ciencia #Salud #Demencia #TREM2 #Microglia #CistatinaC #Cell #Medicina #26defebrero #felizjueves donporque.com/tumores-que-...

Moriah's talk is on OBS YouTube channel!
Inhibition of ACAT 1 promotes shedding of soluble #TREM2 and #LRP1-dependent #phagocytosis of amyloid beta protein in #microglia (Alzheimers Dement 2025)

*Speaker: Moriah J Hovde (Massachusetts General Hospital)
youtu.be/Xe6Cn5aFrvU

TREM2 in Regulating Macrophage Inflammatory Responses and Disease Pathogenesis

dl.begellhouse.com/journals/2ff...

#TREM2 #Neuroinflammation #Microglia #CRI

🧠 TREM2 Levels Shape Microglial Metabolic Fitness. This study shows that microglial #TREM2 is not an on/off signal but a graded axis that tracks with microglial state and function.

🔗Read a summary of the study on our website: www.synergy-munich.de/news-events/...

¿El cáncer frena el alzhéimer? La pista se llama cistatina C Un estudio en Cell revela cómo tumores liberan cistatina C que cruza al cerebro y activa TREM2 para degradar placas del alzhéimer en ratones. Un equipo de la Huazhong University of Science and Technol...

¿El cáncer frena el alzhéimer? La pista se llama cistatina C #Alzheimer #Ciencia #Salud #Neurociencia #Investigacion #Microglia #TREM2 #Cancer #CistatinaC #Cell #Medicina #27deenero #felizmartes donporque.com/cistatina-c/

Differential downstream signaling in microglia lacking Alzheimer’s-related TREM2 or its adaptor TYROBP/DAP12 - Molecular Neurodegeneration Advances Microglia, the primary immune cell in the brain, have multiple activation phenotypes involved in broad functions within the brain, playing roles in neurotoxicity/neuroprotection, release of inflammato...

Differential downstream signaling in #microglia lacking #Alzheimers -related #TREM2 or its adaptor TYROBP/DAP12

Gabriela E. Farias Quipildor...Stephen R. J. Salton, Michelle E. Ehrlich

link.springer.com/article/10.1...

Muna Therapeutics Commences Phase 1 Trial for Breakthrough Alzheimer's Treatment Muna Therapeutics has initiated its Phase 1 trial of MNA-001, an innovative treatment aimed at improving outcomes for early Alzheimer's patients. The study focuses on safety, tolerability, and effects on neurodegeneration.

Muna Therapeutics Commences Phase 1 Trial for Breakthrough Alzheimer's Treatment #Denmark #Copenhagen #Muna_Therapeutics #TREM2 #Alzheimer's_Treatment

TREM2 in Regulating Macrophage Inflammatory Responses and Disease Pathogenesis

www.dl.begellhouse.com/journals/2ff...

#TREM2 #AlzheimersDisease #Immunology

Microglia TREM2R47H Alzheimer-linked variant enhances excitatory transmission and reduces LTP via increased TNF-α levels Analysis of rats carrying the microglia gene and Alzheimer risk factor Trem2R47H variant shows increased glutamatergic transmission via supraphysiological TNF-α brain concentrations, linking a microgl...

In @elife.bsky.social : Microglia TREM2R47H Alzheimer-linked variant enhances excitatory transmission and reduces LTP via increased TNF-α levels
doi.org/10.7554/eLif...

#AlzheimersResearch #Neuroscience #DementiaRisk #TREM2 #Microglia #BrainHealth

Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands - Molecular Neurodegeneration TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer’s disease and other neurodegenerative diseases. While a number of TREM2 ligands have bee...

I am so thrilled to share our latest collab with @jablab3.bsky.social ! Structural mapping of #TREM2 ligand interactions by #BLI. Led by Jessica Greven; thanks to big contributions by Josh Wydra, Cynthia Zhi,...
molecularneurodegeneration.biomedcentral.com/articles/10....

Two complementary pubs in this thread that detail distinctions and differential functions of homeostatic and reactive microglia in #Alzheimers disease #trem2 #microglia #neuroskyence